

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Microsoft Teams,
Meeting ID: 296 247 871 000
Passcode: Pyhswr

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

STATE OR LOCAL OFFICIALS CONTINUE TO IMPOSE OR RECOMMEND MEASURES TO PROMOTE SOCIAL DISTANCING. AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES. YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aasejo@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: [Microsoft Teams](#) OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MAY SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE OR PROVIDE COMMENT [DURING THE MEETING AT THE END OF EACH TOPIC.](#)

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. DURING EACH AGENDA ITEM, YOU WILL BE PROVIDED A REASONABLE AMOUNT OF TIME TO PROVIDE PUBLIC COMMENT. THE COMMITTEE WOULD APPRECIATE, HOWEVER, IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING.

AGENDA

ITEM VOTE	DESCRIPTION	TIME
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview 	2 min -
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> CalAIM Update NCQA Survey DMHC BHI CGM conversion to MediCalrx Enteral Nutrition conversion to MediCalRX 	15 min -

MCDAC Drug	Indication	CDL Status	Recommendation Based on - Safety, Efficacy, Essential Need, Misuse Potential, etc.	Previous MCAL Status
Genotropin (somatropin) 5mg & 12mg injection and 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8 and 2 mg miniquick injection	Growth Failure	F-PA	Keep F-PA	NF
Saxenda (liraglutide) 6mg/mL pre-filled pen	Chronic Weight Management	F-PA	Keep F-PA	F-PA
Wegovy (semaglutide) 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL, 1.7mg/0.75mL pre-filled pen injector	Chronic Weight Management	F-PA	Keep F-PA	F-PA

III) Pharmacy Utilization Reports (Quarter 2, 2022)

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

10 min

10
mi
n -

- Top 50 Drugs by Cost
- Top 50 PA Reviewed Drugs

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes

Estimated Date of Public Disclosure: 9/20/2022 (formulary changes only; no trade secrets will be disclosed).

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Ashley Asejo, Pharmacy Services Specialist, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
GLP-1 agonists class review	• No change
Hepatitis B class review	• No change
Dry eye disease class review	• No change
Laxatives class review	• No change
Pancreatic enzymes class review	• No change
Peak flow meters class review	• No change
Mounjaro monograph	• No change
Medication Request Guidelines	Changes
White Blood Cell Stimulators	• Add new agent Releuko
Inhaler Assistant Devices	• Remove MCAL and IHSS language
Safety Edit Exception	• Add day supply limit error to list of exceptions and criteria for review • Minor language changes for clarity
Antiemetics	• Remove MCAL and IHSS language • Add Anzemet to non-formulary medications list. Remove Varubi IV from list- obsolete. • Change brand generic status of Emend IV
Mesalamine	• Wording updates to account for Pentasa 500 mg's generic availability
Gonadotropin Releasing Hormone Antagonist Combination Products	• Minor wording change for clarity
Topical Antibiotics	• Remove MCAL language and formulary statuses
Corticosteroids for Ulcerative Colitis and Crohn's disease	• Minor word changes for clarity
Alosetron (Lotronex)	• Change initial approval to 3 months

10
mi
n E
V

Viberzi (eluxadoline)	<ul style="list-style-type: none"> Change initial approval to 3 months
Vancomycin	<ul style="list-style-type: none"> Minor wording update in criteria statement
Scabicides and Pediculicides	<ul style="list-style-type: none"> Remove duplicative language
Rifamycin Antibiotics	<ul style="list-style-type: none"> Remove MCAL and IHSS language
Topical Acne Agents	<ul style="list-style-type: none"> Minor punctuation changes
Tranexamic acid (Lysteda)	<ul style="list-style-type: none"> Update criteria statement wording
Makena	<ul style="list-style-type: none"> No change
Rifabutin (Mycobutin)	<ul style="list-style-type: none"> No change
Atovaquone-proguanil (Malarone)	<ul style="list-style-type: none"> No change
Intranasal Steroids	<ul style="list-style-type: none"> No change
Ophthalmic Anti-Inflammatory Agents	<ul style="list-style-type: none"> No change
Quantity Limit Exception	<ul style="list-style-type: none"> No change
Nuedexta	<ul style="list-style-type: none"> No change
Cartilaginous Repair Agents	<ul style="list-style-type: none"> No change
Memantine ER (Namenda XR)	<ul style="list-style-type: none"> No change
Desvenlafaxine succinate (Pristiq)	<ul style="list-style-type: none"> No change
Physician Administered Medication (PAD)/ Medical Benefit Guidelines	<ul style="list-style-type: none"> No change
Dronabinol	<ul style="list-style-type: none"> No change
Erythropoiesis-Stimulating Agents	<ul style="list-style-type: none"> No change
Injectable/Infusible Bone-Modifying Agents for Oncology Indications	<ul style="list-style-type: none"> No change
Moxifloxacin Oral Tablet	<ul style="list-style-type: none"> No change
Spravato (esketamine) Intranasal	<ul style="list-style-type: none"> No change
Santyl Ointment	<ul style="list-style-type: none"> No change
Tetracycline Antibiotics	<ul style="list-style-type: none"> No change
Adenosine Triphosphate-Citrate Lyase (ACL) inhibitors	<ul style="list-style-type: none"> No change
Physician Administered Drug (PAD) Guidelines	Changes
Adakveo	<ul style="list-style-type: none"> Change the initial authorization period to 12 months
Exondys 51	<ul style="list-style-type: none"> Minor capitalization change
Erythropoiesis-Stimulating Agents	<ul style="list-style-type: none"> Add coverage duration provision for chronic conditions Add statement regarding labeled indications for biosimilars
White Blood Cell Stimulators	<ul style="list-style-type: none"> Add new biosimilar Releuko Add statement regarding labeled indications for biosimilars

Iron-containing Products	<ul style="list-style-type: none"> Remove “in adult patients” and adjust language to “age appropriate FDA approved dose”
Aduhelm	<ul style="list-style-type: none"> No change
Interim Formulary Updates	
<ul style="list-style-type: none"> See p. XX in packet 	
Pharmacy Policy & Procedure Updates	
<ul style="list-style-type: none"> RX-002 Prior Authorization Review Process 	<ul style="list-style-type: none"> Covered benefit expansion to include medications treating gender dysphoria, mental health or substance use.
<ul style="list-style-type: none"> RX-004 Formulary Management 	<ul style="list-style-type: none"> Covered benefit expansion to include medications treating gender dysphoria, mental health or substance use.
<ul style="list-style-type: none"> RX-013 Physician/Facility-Administered Drugs (PAD) Prior Authorization Review Process 	<ul style="list-style-type: none"> New Policy & Procedure for review
P&T Meeting Minutes	
<ul style="list-style-type: none"> P&T Meeting Minutes Q2 June 21, 2022 	

V)

New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Fertility Agents MRG - new
- Erectile Dysfunction Medications MRG - new

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

- Chelating agents class review
- SGLT-2 class review
- Ibsrela monograph

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

Review:

- Vaginal Progesterone
- Biologic Agents for Nasal Polyposis
- Interleukin Receptor Antagonists for Eosinophilic Conditions
- Multaq (dronedarone)
- Long-Acting Basal Insulin
- Constipation agents
- Opioid Use Disorder (OUD) Agents
- Medications for the treatment of Multi-Drug Resistant Tuberculosis
- Orilissa (elagolix)
- Injectable/Infusible Agents for Osteoporosis and Paget’s Disease
- Specialty Biological Agents for Crohn’s Disease
- Off-label uses
- Non-Formulary and PA Required Medications without Drug-Specific Criteria
- Drugs for Gender Dysphoria For Less Than 21 Years Old
- Drugs for Gender Dysphoria For At Least 21 Years Old

45
min

V

VIII) Physician Administered Drug (PAD) Policies

Natalee Felten, PharmD, Pharmacist, PerformRx

10 min **V**

1. Injectable/Infusible Agents for Osteoporosis and Paget’s Disease

IX) Informational Updates on New Developments in Pharmacy

Natalee Felten, PharmD, Pharmacist, PerformRx

2 min

- New Product Review

X) Old Business

Natalee Felten, PharmD, Pharmacist, PerformRx

2 min

- None

RECONVENE IN OPEN SESSION

XI) Public Comment

XII) Adjournment

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2023 P&T MEETINGS
December 20 th 2022	March 21 st 2023
	June 20 th 2023
	September 26th 2023
	December 19 th 2023

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.